![]() | ![]() |
Formats:
|
||||||||||||
The role of programmed-1 ribosomal frameshifting in coronavirus propagation 1 Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 2 Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland Send correspondence to: Ewan Plant, CBER, FDA, HFM-310, 8800 Rockville Pike, Bethesda MD 20892, Tel: 301-827-1954, Fax: 301-480-4757, E-mail: Ewan.Plant/at/FDA.hhs.gov The publisher's final edited version of this article is available at Front Biosci.Abstract Coronaviruses have the potential to cause significant economic, agricultural and health problems. The severe acute respiratory syndrome (SARS) associated coronavirus outbreak in late 2002, early 2003 called attention to the potential damage that coronaviruses could cause in the human population. The ensuing research has enlightened many to the molecular biology of coronaviruses. A programmed -1 ribosomal frameshift is required by coronaviruses for the production of the RNA dependent RNA polymerase which in turn is essential for viral replication. The frameshifting signal encoded in the viral genome has additional features that are not essential for frameshifting. Elucidation of the differences between coronavirus frameshift signals and signals from other viruses may help our understanding of these features. Here we summarize current knowledge and add additional insight regarding the function of the programmed -1 ribosomal frameshift signal in the coronavirus lifecycle. Keywords: Coronavirus, SARS, Frameshifting, Review 2. INTRODUCTION The Coronaviridae family is comprised of toroviruses and at least three groups of coronaviruses which, together with the Arteriviridae and Roniviridae, belong to the order Nidovirales (1; http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/index.htm). The arteriviruses and coronaviruses can cause enteric and respiratory tract infections in mammals and birds while the roniviruses infect fish. The severity of pathogenesis varies depending on viral genotype. Outbreaks sometimes result in diarrhea and loss of livestock. After the SARS (severe acute respiratory syndrome) associated coronavirus epidemic in 2002–2003 interest and research in coroniviruses increased dramatically. Unlike the previously identified human coronaviruses (HCoV-229E and HCoV-OC43) which are more commonly associated with inconsequential respiratory infection, SARS-CoV had a mortality rate of 9.6% (2; http://www.who.int/csr/sars/country/table2004_04_21/en/index.html). The resulting resurgence in interest has added to decades of work from a few groups and has advanced our knowledge of the coronavirus lifecycle considerably. This article focuses on how these viruses manipulate the host protein synthetic machinery to produce proteins essential for viral replication via a mechanism called programmed -1 ribosomal frameshifting (-1 PRF). We describe salient features and how study of the frameshifting mechanism may enhance our understanding of other parts of the viral lifecycle. 3. Coronavirus Lifecycle Successful infection of host cells requires many steps which are common to all coronaviruses (Figure 1
Viruses by definition are dependent on the host cellular machinery for replication. However, as the viral lifecycle progresses inside the cell, the virus not only usurps certain host enzymes, but it also generates proteins that are not available from the host repertoire. For example, translation of viral proteins from the initial infectious RNA utilizes the host ribosomes while generation of new virus RNA requires a virally encoded RNA dependent RNA polymerase (RDRP). Many coronavirus proteins are translated from subgenomic RNAs (sgRNAs) rather than the genomic RNA (Figure 2 ORF1a/b, which is translated in the first phase, is a polyprotein that is cleaved into 16 non-structural proteins (Figure 2 Production of proteins from ORF1a/b does not follow the usual rules of translation. Two polyproteins are produced during the translation of one disjointed open reading frame. The first polyprotein is encoded entirely within ORF1a and translation terminates at the stop codon that defines ORF1a, as is typical in normal translation. However, there are signals contained within the RNA prior to the stop codon that direct a fraction of elongating ribosomes into an alternative reading frame, allowing them to bypass the ORF1a termination codon and continue translation into ORF1b, creating a larger polyprotein. This redirection of the ribosomes to create two polyproteins has been demonstrated for many viruses including arteriviruses (8), roniviruses (9) and a number of coronaviruses (10–13). The mechanism by which the ribosomes are redirected is called programmed -1 ribosomal frameshifting (-1 PRF). It is often at least 2-orders of magnitude more efficient than baseline rates ribosomal error. The efficiency of a -1 PRF may range from 15–60% depending on the assay system and the amount of RNA flanking the core sequence (14–16). This suggests that the flanking sequences are of some importance; however, codon and reading frame constraints pose some limitations on analyses of these flanking sequences using current in vitro assay systems. Until the relatively recent emergence of a variety of molecular and viral tools specific to coronaviruses the pursuit of these issues has been limited. The following section describes how our understanding of -1 PRF has advanced with particular emphasis on the many contributions made by analysis of coronavirus frameshift signals. 4. Programmed Frameshifting Programmed -1 ribosomal frameshifting (-1 PRF) is a mechanism used to regulate gene expression at the level of protein synthesis. As ribosomes translate one ORF they encounter a signal in the mRNA that directs a fraction of them to shift into an alternative downstream ORF which is in the -1 phase relative to the initiating upstream ORF (Figure 3
-1 PRF signals are usually composed of a “slippery site” followed by a stimulatory structure. These two elements are typically separated by a short spacer region. The slippery site is composed of a heptameric sequence such that the A- and P-site tRNAs can un-pair from the mRNA and re-pair in the -1 reading frame (20; Figure 3 While the stimulatory structure was initially postulated to be a simple mRNA stem-loop studies of the IBV -1 PRF signal provided the first evidence for the requirement of a more complex mRNA pseudoknot (27; Figure 4
A number of models have been proposed to describe the mechanism by which -1 PRF occurs (20–24). All the models posit that the stimulatory element causes a pause in translation and that base-pairing is required at the non-wobble positions of at least two tRNA molecules to the mRNA after the frameshift (Figure 3 5. WHAT IS THE ROLE OF -1 PRF IN THE CORONAVIRUS LIFECYCLE? While progress has been made on elucidating the mechanism of -1 programmed ribosomal frameshifting and the RNA sequences involved in coronaviruses, the requirement for -1 PRF in the lifecycle of this class of viruses remains obscure. For other viruses, such as HIV and the yeast totivirus L-A, frameshifting regulates the relative ratios of structural to enzymatic proteins. The relative abundance of the coat proteins to viral RNA affects packaging and deviations from the optimal ratio result in a loss of infectivity (36–38). In contrast, -1PRF in coronaviruses modulates the relative ratios of two different classes of enzymatic proteins: proteases (and other uncharacterized proteins) encoded by the upstream Orf1a, and RDRPs and RNA modifying enzymes encoded by Orf1b. As coronavirus structural proteins are encoded on sgRNAs (the transcription of which is dependent on the frameshift), the role of -1 PRF on both the levels and timing of their synthesis, and on virus propagation in general has not yet been characterized. More specifically, the functional domains of the predicted proteases are encoded in nsp3 and nsp5 within ORF1a, prior to the -1 PRF site. The RNA modifying functions (RNA dependent RNA polymerase, helicase, exoribonuclease, uridylate-specific endoribonuclease and S-adenoslmethionine-dependent ribose 2′-O-methyltransferase) are encoded in nsp12–16 after the -1 PRF site (Figure 2 The genomic RNA from plus-strand RNA viruses serves at least two functions during infection: 1) it acts as the mRNA from which viral proteins are translated, and 2) it is the template from which new genomic and subgenomic RNA is transcribed. How the infectious RNA transitions from one function to the other remains unanswered. Some progress has been made in our understanding of how another plus-strand RNA virus, the Barley yellow dwarf virus (BYDV) regulates ribosome and replicase traffic on an RNA template (40). Unlike the SARS coronavirus which utilizes a pseudoknot for frameshifting, BYDV requires a kissing-loop interaction similar to that described for the human coronavirus 229E frameshifting (32). The model requires disruption of long range RNA:RNA interactions which, if they do not reform, allow a switch between translation and transcription. In BWYV, interactions between a sgRNA and the genomic RNA also inhibit translation of the genomic RNA leaving it available for transcription or packaging (41). Such long range RNA:RNA interactions or interactions between gRNA and sgRNAs have not yet been identified in coronaviruses. An RNA switch in the 3′ UTR of MHV has been characterized and found to be essential (42). This motif is found in all group 2 coronavirus sequences but only the 5′ or 3′ portion appears to be conserved in group 1 or group 3 coronaviruses. Interestingly a third stem-loop in the pseudoknot of the -1 PRF signal is predicted to be conserved among the group 2 coronavirus but not in the group 1 coronaviruses which utilize a kissing-loop for frameshifting (15). Some alterations to the third stem in the SARS coronavirus pseudoknot result in a loss of infectivity without dramatically affecting frameshifting, and a subset of viral proteins encoded by the subgenomic RNAs have been identified that bind to the pseudoknot in the SARS -1 PRF signal (Plant and Dinman, unpublished data). These findings suggest that this region of the SARS (+) strand is vital for an aspect of the virus lifecycle other than -1 PRF. One current research challenge lies in producing mutations having only moderate effects on -1 PRF so that more meaningful virology can be pursued. As these mutant viruses and replicons become available we will be able to correlate the efficiency of frameshifting with production of genomic and subgenomic RNAs, and with viral titers. It is expected that some of these mutations will result in defects that will give insight into the function of the internal stem loop (stem 3) of the frameshift signal, and that that the insight thus gained will provide an alternative starting point for dissecting the coronavirus replication system. 6. PERSPECTIVES The prospects for studies of both -1 PRF and coronaviruses are encouraging. A number of synergistic advances are being made in both areas. The constantly expanding number of coronavirus sequences is enhancing the ability of researchers to identify conserved RNA sequence and structural motifs with a greater degree of confidence. As critical elements are identified experiments can be thoughtfully designed to generate mutant viruses and replicons from which useful information can be acquired. The size of the coronavirus genome and the lack of unique restriction sites for cloning pose some difficulties in manipulation of the virus. However recent advances in the stability of plasmid vectors and the availability of class II restriction endonucleases or restriction enzymes that cleave adjacent to the recognition sequence have circumvented some of these difficulties (43). The available clones and replicons (44–45) have allowed many groups to readily investigate different aspects of the coronavirus lifecycle. Developments in the NMR field are also enabling the solution of larger RNA structures such as those that direct -1 PRF. In addition, advances are being made in the design of algorithms able to predict tertiary RNA structures such as frameshift-promoting mRNA pseudoknots (46–48). As more structural data are generated the computational algorithms will be refined which in turn will provide enhanced tools for experimental design by bench-based researchers. The coronavirus frameshift signals are complex and diverse and, as described above, have yielded a wealth of molecular biological data describing features important for -1 PRF. As noted previously, there are several limitations to -1 PRF studies, the most pertinent being that there are two overlapping open reading frames to maintain. Obviously silent protein coding mutations are preferable so that only recoding events are analyzed rather than protein function. The termination codon for the first ORF is very early in the SARS -1 PRF signal compared to the position of stop codons in other frameshift signals and this has increased the variety of mutations that can be sustained. A further limitation is that a frameshifting event must occur for production of the RNA dependent RNA polymerase which is essential for virus production. Thus mutations which abolish frameshifting completely will not produce replicative or infectious virus. It has been shown for some other viruses that there is an apparent threshold level of frameshifting required for competent virus production (36–38). Mutations that subtly alter the frequency of -1PRF in the coronavirus context are being discovered and these will lead to a greater understanding of the role of -1PRF in coronavirus replication. Acknowledgments Many of the published research articles would not have been possible without the free exchange of reagents and collaborations set up between groups with different expertise. The rapid emergence and severity of the SARS associated coronavirus lead to the sharing of unpublished information at conferences and meetings which in turn added vigor to the field. Because of the competitive nature of research, this sharing of resources is dependent on the ethical behavior of the researchers. We thank all those who are part of the community and have contributed important information that has the potential to prevent or control virus spread should a similar outbreak occur in the future. This work was supported by NIH grant RO1 AI064307. The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy. Abbreviations References 1. Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, Guan Y. Evolutionary insights into the ecology of coronaviruses. J Virol. 2007;81:4012–20. [PubMed] 2. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69:635–64. [PubMed] 3. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292. [PubMed] 4. de Haan CA, Rottier PJ. Hosting the severe acute respiratory syndrome coronavirus: specific cell factors required for infection. Cell Microbiol. 2006;8:1211–8. [PubMed] 5. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol. 2007;81:20–9. [PubMed] 6. Ziebuhr J. The coronavirus replicase. Curr Top Microbiol Immunol. 2005;287:57–94. [PubMed] 7. Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, Onderwater JJ, van der Meulen J, Koerten HK, Mommaas AM. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. 2006;80:5927–40. [PubMed] 8. den Boon JA, Snijder EJ, Chirnside ED, de Vries AA, Horzinek MC, Spaan WJ. Equine arteritis virus is not a togavirus but belongs to the coronaviruslike superfamily. J Virol. 1991;65:2910–20. [PubMed] 9. Cowley JA, Dimmock CM, Spann KM, Walker PJ. Gill-associated virus of Penaeus monodon prawns: an invertebrate virus with ORF1a and ORF1b genes related to arteri- and coronaviruses. J Gen Virol. 2000;81:1473–84. [PubMed] 10. Brierley I, Boursnell ME, Binns MM, Bilimoria B, Blok VC, Brown TD, Inglis SC. An efficient ribosomal frame-shifting signal in the polymerase-encoding region of the coronavirus IBV. EMBO J. 1987;6:3779–85. [PubMed] 11. Bredenbeek PJ, Pachuk CJ, Noten AF, Charité J, Luytjes W, Weiss SR, Spaan WJ. The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHV-A59; a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism. Nucleic Acids Res. 1990;18:1825–32. [PubMed] 12. Herold J, Raabe T, Schelle-Prinz B, Siddell SG. Nucleotide sequence of the human coronavirus 229E RNA polymerase locus. Virology. 1993;195:680–91. [PubMed] 13. Thiel V, Ivanov KA, Putics A, Hertzig T, Schelle B, Bayer S, Weissbrich B, Snijder EJ, Rabenau H, Doerr HW, Gorbalenya AE, Ziebuhr J. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol. 2003;84:2305–15. [PubMed] 14. Baranov PV, Henderson CM, Anderson CB, Gesteland RF, Atkins JF, Howard MT. Programmed ribosomal frameshifting in decoding the SARS-CoV genome. Virology. 2005;332:498–510. [PubMed] 15. Plant EP, Pérez-Alvarado GC, Jacobs JL, Mukhopadhyay B, Hennig M, Dinman JD. A three-stemmed mRNA pseudoknot in the SARS coronavirus frameshift signal. PLoS Biol. 2005;3:e172. [PubMed] 16. Su MC, Chang CT, Chu CH, Tsai CH, Chang KY. An atypical RNA pseudoknot stimulator and an upstream attenuation signal for -1 ribosomal frameshifting of SARS coronavirus. Nucleic Acids Res. 2005;33:4265–75. [PubMed] 17. Jacks T, Varmus HE. Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. Science. 1985;230:1237–42. [PubMed] 18. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature. 1988;331:280–3. [PubMed] 19. Boursnell ME, Brown TD, Foulds IJ, Green PF, Tomley FM, Binns MM. The complete nucleotide sequence of avian infectious bronchitis virus: analysis of the polymerase-coding region. Adv Exp Med Biol. 1987;218:15–29. [PubMed] 20. Jacks T, Madhani HD, Masiarz FR, Varmus HE. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell. 1988;55:447–58. [PubMed] 21. Weiss RB, Dunn DM, Shuh M, Atkins JF, Gesteland RF. E. coli ribosomes re-phase on retroviral frameshift signals at rates ranging from 2 to 50 percent. New Biol. 1989;1:159–69. [PubMed] 22. Farabaugh PJ. Programmed translational frameshifting. Microbiol Rev. 1996;60:103–34. [PubMed] 23. Plant EP, Jacobs KL, Harger JW, Meskauskas A, Jacobs JL, Baxter JL, Petrov AN, Dinman JD. The 9-A solution: how mRNA pseudoknots promote efficient programmed -1 ribosomal frameshifting. RNA. 2003;9:168–74. [PubMed] 24. Léger M, Dulude D, Steinberg SV, Brakier-Gingras L. The three transfer RNAs occupying the A, P and E sites on the ribosome are involved in viral programmed -1 ribosomal frameshift. Nucleic Acids Res. 2007;35:5581–92. [PubMed] 25. Brierley I, Meredith MR, Bloys AJ, Hagervall TG. Expression of a coronavirus ribosomal frameshift signal in Escherichia coli: influence of tRNA anticodon modification on frameshifting. J Mol Biol. 1997;270:360–73. [PubMed] 26. Plant EP, Dinman JD. Comparative study of the effects of heptameric slippery site composition on -1 frameshifting among different eukaryotic systems. RNA. 2006;12:666–73. [PubMed] 27. Brierley I, Digard P, Inglis SC. Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot. Cell. 1989;57:537–47. [PubMed] 28. Morikawa S, Bishop DH. Identification and analysis of the gag-pol ribosomal frameshift site of feline immunodeficiency virus. Virology. 1992;186:389–97. [PubMed] 29. Kollmus H, Honigman A, Panet A, Hauser H. The sequences of and distance between two cis-acting signals determine the efficiency of ribosomal frameshifting in human immunodeficiency virus type 1 and human T-cell leukemia virus type II in vivo. J Virol. 1994;68:6087–91. [PubMed] 30. Napthine S, Liphardt J, Bloys A, Routledge S, Brierley I. The role of RNA pseudoknot stem 1 length in the promotion of efficient -1 ribosomal frameshifting. J Mol Biol. 1999;288:305–20. [PubMed] 31. Bekaert M, Rousset JP. An extended signal involved in eukaryotic -1 frameshifting operates through modification of the E site tRNA. Mol Cell. 2005;17:61–8. [PubMed] 32. Herold J, Siddell SG. An ‘elaborated’ pseudoknot is required for high frequency frameshifting during translation of HCV 229E polymerase mRNA. Nucleic Acids Res. 1993;21:5838–42. [PubMed] 33. Dos Ramos F, Carrasco M, Doyle T, Brierley I. Programmed -1 ribosomal frameshifting in the SARS coronavirus. Biochem Soc Trans. 2004;32:1081–3. [PubMed] 34. Snijder EJ, den Boon JA, Bredenbeek PJ, Horzinek MC, Rijnbrand R, Spaan WJ. The carboxyl-terminal part of the putative Berne virus polymerase is expressed by ribosomal frameshifting and contains sequence motifs which indicate that toro- and coronaviruses are evolutionarily related. Nucleic Acids Res. 1990;18:4535–42. [PubMed] 35. Brierley I, Rolley NJ, Jenner AJ, Inglis SC. Mutational analysis of the RNA pseudoknot component of a coronavirus ribosomal frameshifting signal. J Mol Biol. 1991;220:889–902. [PubMed] 36. Dinman JD, Wickner RB. Ribosomal frameshifting efficiency and gag/gag-pol ratio are critical for yeast M1 double-stranded RNA virus propagation. J Virol. 1992;66:3669–76. [PubMed] 37. Hung M, Patel P, Davis S, Green SR. Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication. J Virol. 1998;72:4819–24. [PubMed] 38. Biswas P, Jiang X, Pacchia AL, Dougherty JP, Peltz SW. The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy. J Virol. 2004;78:2082–7. [PubMed] 39. Imbert I, Guillemot JC, Bourhis JM, Bussetta C, Coutard B, Egloff MP, Ferron F, Gorbalenya AE, Canard B. A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus. EMBO J. 2006;25:4933–42. [PubMed] 40. Barry JK, Miller WA. A -1 ribosomal frameshift element that requires base pairing across four kilobases suggests a mechanism of regulating ribosome and replicase traffic on a viral RNA. Proc Natl Acad Sci U S A. 2004;99:11133–8. [PubMed] 41. Shen R, Rakotondrafara AM, Miller WA. trans regulation of cap-independent translation by a viral subgenomic RNA. J Virol. 2006;80:10045–54. [PubMed] 42. Goebel SJ, Miller TB, Bennett CJ, Bernard KA, Masters PS. A hypervariable region within the 3′ cis-acting element of the murine coronavirus genome is nonessential for RNA synthesis but affects pathogenesis. J Virol. 2004;81:1274–84. [PubMed] 43. Baric RS, Sims AC. Development of mouse hepatitis virus and SARS-CoV infectious cDNA constructs. Curr Top Microbiol Immunol. 2005;287:229–52. [PubMed] 44. Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, Prentice E, Denison MR, Geisbert TW, Baric RS. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2003;100:12995–3000. [PubMed] 45. Almazán F, Dediego ML, Galán C, Escors D, Alvarez E, Ortego J, Sola I, Zuñiga S, Alonso S, Moreno JL, Nogales A, Capiscol C, Enjuanes L. Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J Virol. 2006;80:10900–6. [PubMed] 46. Reeder J, Steffen P, Giegerich R. pknotsRG: RNA pseudoknot folding including near-optimal structures and sliding windows. Nucleic Acids Res. 2007;35:W320–4. [PubMed] 47. Dawson WK, Fujiwara K, Kawai G. Prediction of RNA pseudoknots using heuristic modeling with mapping and sequential folding. PLoS ONE. 2007;2:e905. [PubMed] 48. Jacobs JL, Belew AT, Rakauskaite R, Dinman JD. Identification of functional, endogenous programmed -1 ribosomal frameshift signals in the genome of Saccharomyces cerevisiae. Nucleic Acids Res. 2007;35:165–74. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||
J Virol. 2007 Apr; 81(8):4012-20.
[J Virol. 2007]Microbiol Mol Biol Rev. 2005 Dec; 69(4):635-64.
[Microbiol Mol Biol Rev. 2005]Adv Virus Res. 2006; 66():193-292.
[Adv Virus Res. 2006]Cell Microbiol. 2006 Aug; 8(8):1211-8.
[Cell Microbiol. 2006]J Virol. 2007 Jan; 81(1):20-9.
[J Virol. 2007]Curr Top Microbiol Immunol. 2005; 287():57-94.
[Curr Top Microbiol Immunol. 2005]J Virol. 2007 Jan; 81(1):20-9.
[J Virol. 2007]J Virol. 2006 Jun; 80(12):5927-40.
[J Virol. 2006]J Virol. 1991 Jun; 65(6):2910-20.
[J Virol. 1991]J Gen Virol. 2000 Jun; 81(Pt 6):1473-84.
[J Gen Virol. 2000]EMBO J. 1987 Dec 1; 6(12):3779-85.
[EMBO J. 1987]J Gen Virol. 2003 Sep; 84(Pt 9):2305-15.
[J Gen Virol. 2003]Virology. 2005 Feb 20; 332(2):498-510.
[Virology. 2005]Science. 1985 Dec 13; 230(4731):1237-42.
[Science. 1985]Nature. 1988 Jan 21; 331(6153):280-3.
[Nature. 1988]EMBO J. 1987 Dec 1; 6(12):3779-85.
[EMBO J. 1987]Cell. 1988 Nov 4; 55(3):447-58.
[Cell. 1988]Cell. 1989 May 19; 57(4):537-47.
[Cell. 1989]J Mol Biol. 1999 May 7; 288(3):305-20.
[J Mol Biol. 1999]Nucleic Acids Res. 2007; 35(16):5581-92.
[Nucleic Acids Res. 2007]Mol Cell. 2005 Jan 7; 17(1):61-8.
[Mol Cell. 2005]Nucleic Acids Res. 1993 Dec 25; 21(25):5838-42.
[Nucleic Acids Res. 1993]Biochem Soc Trans. 2004 Dec; 32(Pt 6):1081-3.
[Biochem Soc Trans. 2004]Nucleic Acids Res. 1990 Aug 11; 18(15):4535-42.
[Nucleic Acids Res. 1990]PLoS Biol. 2005 Jun; 3(6):e172.
[PLoS Biol. 2005]Nucleic Acids Res. 2005; 33(13):4265-75.
[Nucleic Acids Res. 2005]Cell. 1988 Nov 4; 55(3):447-58.
[Cell. 1988]Nucleic Acids Res. 2007; 35(16):5581-92.
[Nucleic Acids Res. 2007]Nature. 1988 Jan 21; 331(6153):280-3.
[Nature. 1988]J Mol Biol. 1997 Jul 18; 270(3):360-73.
[J Mol Biol. 1997]RNA. 2006 Apr; 12(4):666-73.
[RNA. 2006]J Virol. 1992 Jun; 66(6):3669-76.
[J Virol. 1992]J Virol. 2004 Feb; 78(4):2082-7.
[J Virol. 2004]EMBO J. 2006 Oct 18; 25(20):4933-42.
[EMBO J. 2006]J Virol. 2007 Jan; 81(1):20-9.
[J Virol. 2007]Proc Natl Acad Sci U S A. 2002 Aug 20; 99(17):11133-8.
[Proc Natl Acad Sci U S A. 2002]Nucleic Acids Res. 1993 Dec 25; 21(25):5838-42.
[Nucleic Acids Res. 1993]J Virol. 2006 Oct; 80(20):10045-54.
[J Virol. 2006]J Virol. 2007 Feb; 81(3):1274-87.
[J Virol. 2007]PLoS Biol. 2005 Jun; 3(6):e172.
[PLoS Biol. 2005]Curr Top Microbiol Immunol. 2005; 287():229-52.
[Curr Top Microbiol Immunol. 2005]Proc Natl Acad Sci U S A. 2003 Oct 28; 100(22):12995-3000.
[Proc Natl Acad Sci U S A. 2003]J Virol. 2006 Nov; 80(21):10900-6.
[J Virol. 2006]Nucleic Acids Res. 2007 Jul; 35(Web Server issue):W320-4.
[Nucleic Acids Res. 2007]Nucleic Acids Res. 2007; 35(1):165-74.
[Nucleic Acids Res. 2007]J Virol. 1992 Jun; 66(6):3669-76.
[J Virol. 1992]J Virol. 2004 Feb; 78(4):2082-7.
[J Virol. 2004]